Abstract: Provided is a display module, including a base substrate, a plurality of light-emitting patterns, and a plurality of microlens groups corresponding to the light-emitting patterns. An orthographic projection region of at least one of the light-emitting patterns on the base substrate forms a primary display region. The plurality of microlens groups are disposed on a side, distal from the base substrate, of the plurality of light-emitting patterns. An orthographic projection of the microlens group on the base substrate is within the primary display region formed by the corresponding light-emitting pattern. The microlens group includes at least two microlens structures, and a gap is defined between any adjacent two microlens structures. The light-emitting pattern includes a target region. An orthographic projection of the target region on the base substrate is overlapped with an orthographic projection of the gap on the base substrate. The target region does not emit light.

Abstract: An organic-inorganic hierarchical ZSM-5, a preparation method thereof, and an application thereof are provided. The preparation method for the organic-inorganic hierarchical ZSM-5 includes the following steps: mixing a silicon source, an aluminum source, NaOH, and water, stirring the mixture until uniformly dispersed, and drying and grinding the mixture to obtain a hierarchical ZSM-5 precursor; mixing the hierarchical ZSM-5 precursor, sodium silicate, seed, ethanol, and water, and uniformly dispersing the mixture to obtain a crystallized solution; mixing the crystallized solution with a hydrolyzed organosilane to obtain a first solution; subjecting the first solution to hydrothermal crystallization at 160-180° C. for 48-72 h to obtain a second product; and washing and drying the second product to obtain the organic-inorganic hierarchical ZSM-5.

Abstract: An organic-inorganic hierarchical ZSM-5, a preparation method thereof, and an application thereof are provided. The preparation method for the organic-inorganic hierarchical ZSM-5 includes the following steps: mixing a silicon source, an aluminum source, NaOH, and water, stirring the mixture until uniformly dispersed, and drying and grinding the mixture to obtain a hierarchical ZSM-5 precursor; mixing the hierarchical ZSM-5 precursor, sodium silicate, seed, ethanol, and water, and uniformly dispersing the mixture to obtain a crystallized solution; mixing the crystallized solution with a hydrolyzed organosilane to obtain a first solution; subjecting the first solution to hydrothermal crystallization at 160-180° C. for 48-72 h to obtain a second product; and washing and drying the second product to obtain the organic-inorganic hierarchical ZSM-5.

Abstract: Disclosed are a display substrate and a manufacturing method thereof. The display substrate includes: a base substrate; multiple first electrodes on the base substrate, where each of the multiple first electrodes includes a transparent conductive portion and a reflective conductive portion; a light-emitting function layer on a side of the multiple first electrodes facing away from the base substrate; an insulation layer between a layer where the multiple first electrodes are located and the base substrate; and multiple reflective structures between the insulation layer and the base substrate. Two adjacent first electrodes are correspondingly provided with one of the multiple reflective structures. The one of the multiple reflective structures includes a first portion and a second portion, an orthographic projection of the first portion on the base substrate and an orthographic projection of one of the two adjacent first electrodes on the base substrate have an overlap area.

Abstract: A display substrate is provided. The display substrate includes a plurality of functional material layers extending at least partially across multiple subpixels. The plurality of functional material layers include a first portion in an inter-subpixel region, and a second portion in subpixel regions. The first portion includes a doped impurity. The first portion and the second portion include at least one functional material in common. A weight percentage of the doped impurity in the first portion is higher than a weight percentage of the doped impurity in the second portion. The first portion spaces apart adjacent subpixels. The second portion includes a light emitting layer of a respective subpixel.

Abstract: The present disclosure provides a display substrate, a manufacturing method thereof and a three-dimensional display apparatus. The display substrate includes a base substrate with a plurality of sub-pixels. Each of the sub-pixels includes at least two first electrodes, and a light-emitting function layer disposed on a side of the first electrodes facing away from the base substrate. Each first electrode includes: a transparent conductive portion and a reflective conductive portion arranged in stack. In at least one of the sub-pixels, two adjacent first electrodes correspond to one reflective structure, the reflective structure includes a first portion and a second portion, an orthographic projection of the first portion on the base substrate and an orthographic projection of one first electrode have an overlap area, and an orthographic projection of the second portion on the base substrate an orthographic projection of another first electrode have an overlap area.

Abstract: A display substrate and a preparation method thereof, a preparation apparatus and a display apparatus are provided, which relate to the technical field of display. The display substrate includes a plurality of light-emitting areas and non-light-emitting areas surrounding respective light-emitting areas. The display substrate includes: a base substrate; a light-emitting functional layer disposed at a side of the base substrate, the light-emitting functional layer including a light-emitting material located in the plurality of light-emitting areas and the non-light-emitting areas. The light-emitting material in the non-light-emitting areas is doped with destructive ions, and the destructive ions are configured for destroying luminescent characteristics of the light-emitting material in the non-light-emitting area.

Abstract: A method for delivering a medication for treatment of a pulmonary disease depending on location(s) of infection lesion(s) within a respiratory tract of a patient is disclosed. The method includes administering metered doses of the medication to the patient having the pulmonary disease by a metered dose inhaler (MDI) actuator having a function of controlling drug particle delivery characteristics. The medication is effective for treating the pulmonary disease. A therapeutically effective amount of medication for treating the pulmonary disease is administered by various metered doses of the medication. The medication includes an active pharmaceutical ingredient (API) associated with treatment of a pulmonary disease. The medication includes a propellant, a co-solvent, and a surfactant. The API is dissolved in the propellant at a pre-determined ratio, with or without a co-solvent. The medication is administered via metered-dose inhalation.

Abstract: The present disclosure introduces pharmaceutical formulations having epinephrine as the active pharmaceutical ingredient (API), and a bile acid, or salt thereof (e.g., sodium taurocholate (STC)) as an absorption enhancer, for intranasal (IN) delivery. The bile acid, or the salt thereof, enhances absorption of epinephrine by IN delivery. Also disclosed are methods of administering epinephrine to a patient by IN delivery using the disclosed epinephrine formulations for various treatments or indications.

Abstract: Disclosed are a display panel and a displaying device. The display panel includes a plurality of first-color subpixels, and each first-color subpixel includes a base, the base including a first driving electrode and a second driving electrode; at least one first electrode, disposed at a side of the base and is connected to the first driving electrode; at least one second electrode, disposed at a same side of the base with the first electrode and is connected to the second driving electrode; an intermediate layer, disposed between the first electrode and the second electrode; wherein the first electrode and the second electrode divide the first-color subpixel into a plurality of secondary pixels, the first electrode and the second electrode are insulated with each other via the intermediate layer, and are respectively connected to the first driving electrode and the second driving electrode, and control the secondary pixels independently.

Abstract: Disclosed are a preparation method of a display panel, a display panel and a displaying device. The display panel comprises a plurality of first-color subpixels, and each first-color subpixel comprises a base, the base comprising a first driving electrode and a second driving electrode; a flat layer disposed on the side, near the first driving electrode and the second driving electrode, of the base; a patterned passivation layer and at least one first electrode disposed on the side, away from the base, of the flat layer, the first electrode being connected with the first driving electrode through via holes penetrating the flat layer; and at least one second electrode disposed on the side, away from the base, of the passivation layer, the second electrode being connected with the second driving electrode through via holes penetrating the passivation layer and the flat layer.

Abstract: Provided are a display panel and a manufacturing method therefor, and a display device. The display panel, including: a base substrate; and a plurality of sub-pixels, located on the base substrate, including a pixel circuit and a light-emitting element, wherein the light-emitting element is connected to the pixel circuit, the pixel circuit is configured to drive the light-emitting element; the light-emitting element includes: a first electrode; and a second electrode, electrically connected to the first electrode, the first electrode is closer to the base substrate than the second electrode.

Abstract: The present disclosure generally pertains to a medical device and more particularly, a metered-dose inhaler (“MDI”) actuator capable of a targeted delivery of fine API particles having particle diameters of about 1.1 ?m or less to a portion of a patient's lungs where alveoli are located.

Abstract: The present disclosure introduces safe and effective pharmaceutical formulations for intranasal delivery. Specifically, the present disclosure introduces the safe clinical use of bile acids or salts thereof as an enhancer to exhibit improved bioavailability and tissue tolerance. In several embodiments, pharmaceutical formulations including bile acids or salts thereof are provided. In several embodiments, the formulations are suitable and/or configured for the intranasal (IN) delivery, methods of manufacturing such formulations, and methods of treating patients using such formulations. The pharmaceutical formulations comprising bile acids, salts of bile acids, and/or combinations thereof. In several embodiments, bile acids, salts of bile acids, and/or combinations thereof are configured for use as absorption enhancers.

Abstract: The present disclosure introduces methods for characterizing iron core carbohydrate colloid drug products, such as iron sucrose drug products. Disclosed methods enable the characterization of the iron core size of the iron core nanoparticles in iron carbohydrates as they exist in the formulation in solution, such as e.g. iron sucrose drug products, and more particularly, the average particle diameter size and size distribution(s) of the iron core nanoparticles. The disclosed methods apply small-angle X-ray scattering (SAXS) in parallel beam transmission geometry, with a sample mounted inside a capillary and centered in the X-ray beam, to iron carbohydrates, such as iron sucrose, in solution without the need to modify the sample, such as to remove unbound carbohydrates, dilute, or dry the sample, to accurately characterize the average iron core particle diameter size of the iron core nanoparticles.

Abstract: The present disclosure relates to an array substrate, a manufacturing method thereof, a three-dimensional display panel, and a display device. The array substrate includes a plurality of sub-pixels arranged in an array. Each sub-pixel includes a first composite region and a second composite region alternately arranged, as well as a substrate; a partition portion formed in the second composite region; a pixel electrode including a first composite electrode formed in the first composite region and a second composite electrode formed on the partition portion; an organic light emitting layer formed on a side of the pixel electrode away from the substrate; a pixel defining layer formed on the substrate provided around the organic light emitting layer; a common electrode having a polarity opposite to the pixel electrode formed on a side of organic light emitting layer away from the substrate; and a packaging layer.

Abstract: The present disclosure introduces intranasal (IN) pharmaceutical formulations having naloxone or an opioid antagonist as the active agent, and an absorption enhancer, such as a bile acid, or a salt thereof, for IN delivery. The bile acid, or salt thereof, enhances absorption of naloxone or an opioid antagonist into the bloodstream of a human subject.

Abstract: Disclosed herein are pharmaceutical formulations including epinephrine that have increased epinephrine retention over long-term storage, e.g., 30-months. In one aspect, a formulation includes: one or more of 0.1 mg/mL of epinephrine or a pharmaceutically acceptable salt thereof provided without any overage, a tonicity regulating agent including 8.2 mg/mL of sodium chloride, a pH adjusting agent including a mixture of 1.5 mg/mL sodium citrate dihydrate, 3.3 mg/mL of citric acid monohydrate, and, optionally, an as-needed amount of sodium hydroxide to maintain the pH level of the formulation within a range of 3.6 to 4.0, 0.075 mg/mL of sodium metabisulfite, and 4 ?g/mL of ethylene diamine tetra-acetate disodium. The formulation has an API recovery of 94.5% or more after at least 30 months of storage at long-term storage conditions defined as 25° C.±2° C. at 1 atmosphere. In addition, in another aspect, a formulation includes 1 mg/mL of epinephrine and other ingredients.

Abstract: Disclosed herein are pharmaceutical formulations including epinephrine that have increased epinephrine retention over long-term storage, e.g., 30-months. In one aspect, a formulation includes: one or more of 0.1 mg/mL of epinephrine or a pharmaceutically acceptable salt thereof provided without any overage, a tonicity regulating agent including 8.2 mg/mL of sodium chloride, a pH adjusting agent including a mixture of 1.5 mg/mL sodium citrate dihydrate, 3.3 mg/mL of citric acid monohydrate, and, optionally, an as-needed amount of sodium hydroxide to maintain the pH level of the formulation within a range of 3.6 to 4.0, 0.075 mg/mL of sodium metabisulfite, and 4 ?g/mL of ethylene diamine tetra-acetate disodium. The formulation has an API recovery of 94.5% or more after at least 30 months of storage at long-term storage conditions defined as 25° C.±2° C. at 1 atmosphere. In addition, in another aspect, a formulation includes 1 mg/mL of epinephrine and other ingredients.